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Minimally Invasive Therapies of Knee Osteoarthritis  
 
Abstract 
Knee osteoarthritis (OA) is a very common disease and a leading cause of 
disability. As the knee is an easy-accessible joint, local intraarticular therapies are raising 
interest as new medications and medical devices are available for injections, since it can 
avoid the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and surgery. 
Our review explores the clinically-evidence effective and minimally invasive treatment 
options available for knee OA management. The search strategy for this literature review 
was conducted by using the key words “knee osteoarthritis” and “intraarticular” and 
“therapeutics” in the PUBMED database. Among the literature, the effectiveness of 
Hyaluronic acid (HA) is controversial. The different molecular mass available has some 
responsibility in this issue. HA formulations with higher molecular mass present 
consistently more positive results in a long time management. Corticosteroids injections 
are effective in acute knee pain and effusion, without long time effect, though. Platelet-
rich plasma have shown positive results among all the literature reviewed, with long time 
effects and disease modifying properties related to its growth factors that promote tissue 
healing and regeneration. A variety of novel therapies have been developed in recent 
years. Among them, mesenchymal stem cells injection is a promising regenerative 
treatment which has shown positive results in two recent randomized controlled trials, 
and it was considered as effective as hyaluronic acid. Genetic therapies using transduced 
chondrocytes expressing TGF-beta also presented promising results in two randomized 
trials. Polynucleotides injections also showed similar results with HA.  Other single 









Knee osteoarthritis (OA) is a very common disease that affects approximately 250 
million people worldwide and is one leading cause of global disability1. The standard 
recommendations of knee OA management consist of nonpharmacological approaches 
(such as weight loss, exercise and braces), followed by analgesic medication, including 
nonsteroidal anti-inflammatory drugs (NSAIDs) and lastly surgery2. A recent study has 
suggested that surgical treatment results in greater pain relief and functional improvement 
compared to nonsurgical treatment, however more serious adverse events are reported in 
surgical treatment3. As knee is an easy-accessible joint, intraarticular therapies have an 
inherent appeal as it mitigates some systemic effects of NSAIDs, including 
gastrointestinal bleeding and myocardial infarction, and avoid adverse events of surgical 
treatment4. The purpose of our study is to evaluate minimally invasive and clinically-
evidence based therapies that can be offered to those patients in which NSAIDs failed to 



















A search was conducted at PUBMED up to October 2016 using the key words 
“knee osteoarthritis” AND “intraarticular” AND “therapeutics”.  Studies published prior 
to 2006, that involved animal experience, were related to surgical procedures/arthroscopy 
or that were not in English or Portuguese were excluded. An abstract quality assessment 
was performed by both authors to exclude low quality studies or others not related with 


























Hyaluronic Acid (“Viscossuplementation”) 
Hyaluronate is a natural component of synovial fluid, acting as a joint lubricant 
and shock absorber. It has a molecular mass ranching from 6500 to 10900 kDa in a normal 
synovial fluid, however in knee OA hyaluronate is depolymerized (molecular mass 2700 
to 4500 kDa) and is cleared at higher rates4.  
17 studies were found using our inclusion/exclusion criteria evaluating clinical 
evidence to use hyaluronic acid (HA) injections in knee OA: 12 clinical trials (Table I) 
and 5 systematic reviews/meta-analysis. Among 7 randomized-controlled trials (RCT) 
accessed, 5 showed superiority of HA injections in pain relief and joint function5-9, 
whereas 2 showed no statistically significant difference compared to placebo10,11. A meta-
analysis conducted by Bannuru et al. evaluating 5 trials with 712 patients with knee OA 
suggested equal efficacy of HA injections compared to oral NSAIDs in terms of pain, 
function and stiffness with a better safety profile for the first option12. In addition, three 
reviews concluded that HA injections could be a safe and efficacious option for knee 
osteoarthritis treatment13-15. On the other hand, a meta-analysis conducted by Rutjes et al. 
analysing 89 trials involving 12667 participants concluded that HA injections have a 
small and clinically irrelevant benefit in terms of pain management in knee OA16. 
 
Table I – Clinical trials evaluating hyaluronic acid in knee osteoarthritis 
Author/year Study design   Conclusions 
Waddell et al. 2015 
17  
Retrospective; 50 patients requiring 
aspiration at the time of 
viscossuplementation compared with 50 
matched patients without effusion 
Effusion requiring aspiration at the time of 
hyaluronic acid injection does not 
negatively impact outcome 
Van der Weegen et 
al. 2015 10 
RCT with 196 patients with knee OA 
comparing HA sodium hyaluronate with 
saline injections; 6 months follow-up 
3 weekly injections of HA (sodium 
hyaluronate) were not superior to saline in 
6 months follow-up 
Petrella, R. J. et al. 
2015 18 
RCT with 98 patients with knee OA 
comparing Hydros, Hydros-TA and 
cross-linked HA single injections; 26 
weeks follow-up 
Single injection of Hydros and Hydros-TA 
is effective in pain relief compared to 
active control; hydros-TA has a faster 
effect 
Leighton, R. et al. 
2014 19 
RCT with 442 patients with knee OA 
comparing NASHA with 
methylprednisolone single injection; 12 
weeks follow-up 
Single injection NASHA was not inferior 
to methylprednisolone at 12 weeks in pain 
score (WOMAC) 
Ishijima M. et al. 
2014 20 
RCT with 200 patients with knee OA 
comparing HA injections with oral 
NSAID; 5 weeks follow-up 
The efficacy of HA injections is not 
inferior to that of NSAIDs and is a more 
safe treatment 
Arden, N. K. et al. 
2014 5 
RCT with 218 patients with knee OA 
comparing NASHA with saline 
injections; 6 weeks follow-up  
NASHA injections has a significant pain 
improvement at 6 weeks follow-up among 
patients without effusion at baseline 
Strand, V. et al. 
2012 6 
RCT with 319 patients with knee OA 
comparing Gel-200 with saline single 
injection; 13 weeks follow-up 
A single injection of Gel-200  is effective 
and well tolerated relieving pain over 13 
weeks 
Navarro-Sarabia, 
F. et al. 2011 7 
RCT with 306 patients with knee OA 
comparing cycles of HA with saline 
injections; 40 months follow-up 
Repeated cycles of HA injections improve 
pain and function in-between cycles and 
this beneficial carry-on for a year after the 
last cycle 
Jorgensen, A. et al. 
2010 11 
RCT with 337 patients with knee OA 
comparing HA sodium hyaluronate with 
saline weekly injections for 5 weeks; 1 
year follow-up 
Five injections of HA (sodium hyaluronate 
- Hyalgan®) did not improve pain, 
function and analgesic consumption over 
3,6,9 and 12 months follow-up 
Chevalier, X. et al. 
2010 8 
RCT with 253 patients with knee OA 
comparing Hylan G-F 20 with saline 
single injection; 26 weeks follow-up 
Single injection  hylan G-F 20 is safe and 
statistically significant in pain relief versus 
placebo 
Altman, R. D. et 
al. 2009 9 
RCT with 588 patients with knee OA 
comparing HA (1% sodium hyaluronate) 
with placebo; 26 weeks follow-up 
Three weekly injection of HA (1% sodium 
hyaluronate) resulted in significant pain 
relief and joint function over a 26 weeks 
follow-up 
Lundsgaard, C. et 
al. 2008 21 
RCT with  251 patients to receive four 
weekly HA sodium hyaluronate 
(Hyalgan®), saline 20 ml (distension) or 
saline 2ml (placebo); 26 weeks follow-up 
No difference between groups reducing 
knee pain  
RCT: Randomized controlled trial; HA:  hyaluronic acid; NSAID: non-steroidal anti-inflammatory drug; NASHA: 
cross-linked (high molecular wheight) HA formulation; Gel-200: cross-linked (high molecular wheight) HA 
formulation; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index;  Hydros: cross-linked 
(high molecular wheight) HA formulation; Hydros-TA: hydros plus 10 mg triancinolone; Hylan G-F 20: high 
molecular wheight (mean 6000 kDa) HA formulation; 
 
Corticosteroids 
Corticosteroids (CS) injections provides pain relief and local anti-inflammatory 
effect by the prostaglandin synthesis inhibition and decreasing collagenases activity. A 
total of 5 studies investigating the efficacy of CS injections were found. One RCT and 
one retrospective pilot study demonstrated that CS injections are effective in pain 
reduction and in functional improvement, being essential prior joint aspiration22,23. CS 
injections are also more suitable for relieving pain in a short-time basis, with a better 
efficacy compared to viscossuplementation in the first 4 weeks24. Another study using a 
different approach concluded that adding triamcinolone to hyaluronic acid improves first-
week symptoms25. A RCT conducted by Bodick et al. reported that an extended-release 
formulation of triamcinolone prolongs and improve pain relief compared to standard 
immediate-release triamcinolone26.   
 
Platelet-rich plasma (PRP) 
Eleven studies evaluating the clinical-evidence of intraarticular platelet-rich 
plasma (PRP) in knee OA were found: four RCT (table II), five non-randomized trials 
and two meta-analysis. All RCT showed that PRP injections are an effective treatment 
for moderate grade knee OA (level 1 of evidence in all studies)27-30, despite the different 
PRP formulations used.  Four non-randomized, single-arm, studies, with a total of 567 
patients receiving PRP injections concluded PRP to be effective in pain reduction and 
function improvement31-34. A non-randomized trial conducted by Kon et al.35 
demonstrated that PRP is more effective reducing pain and symptoms than HA injections.  
A recent meta-analyse conducted by Laudy et al.36 with ten trials comparing PRP 
injections with placebo revealed PRP more effective in pain reduction and function 
improvement at 6 months post-injection. Another meta-analyse reached the same results 
with PRP being an effective treatment for pain reduction compared with pre-treatment 
condition37. Several studies revealed PRP injection being more effective in younger 
patients with low degree of articular degeneration30,31,33,35,37. 
 
Table II – Randomized Controlled Trials evaluating platelets-rich plasm in knee osteoarthritis 
Author/year Study design Conclusions 
Filardo, G. et al. 
2015 27 
RCT, with 192 patients with knee OA 
comparing PRP with HA injections; 12 
months follow-up 
Both treatments are equal 
effective improving function and 
reducing symptoms 
Vaquerizo, V. et al. 
2013 28 
RCT, with 96 patients with knee OA 
comparing PRGF with HA injections; 48 
weeks follow-up 
PRGF proved to be better than 
HA injections in terms of pain 
reduction and functional 
improvement 
Sanchez, M. et al. 
2012 29 
RCT, with 176 patients with knee OA 
comparing PRGF with HA injections; 24 
weeks follow-up 
PRGF showed better short-term 
results compared to HA 
injections in symptoms relief  
Cerza, F. et al. 2012 
30 
RCT, with 120 patients with knee OA 
comparing ACP  with HA injections; 24 
weeks follow-up 
Treatment with ACP showed a 
better clinical outcome 
compared to HA injections 
RCT: randomized controlled trial; OA: osteoarthritis; HA: hyaluronic acid; PRP: platelets-rich plasma; PRGF: 




A variety of new intraarticular therapeutics has been attempted in knee OA. Our 
research found four recent papers related to Mesenchymal Stem Cell (MSC) therapies. A 
RCT with 424 patients with knee OA evaluated the relationship between cell 
concentration in bone marrow aspiration (without MSC isolation and expansion) and pain 
management, concluding that higher cell count ( >4×108 ) is associated with a better 
outcome38. Another RCT comparing a single injection of allogenic bone marrow 
mesenchymal stem cells with HA in 30 randomized patients with knee OA concluded that 
it significantly improved cartilage quality and might be a valid alternative for pain 
management, lacking logistically inconveniences of autologous MSC treatment39. Two 
phase one studies evaluating autologous adipose tissue derived MSC in knee OA patients 
suggested it might be a safe and promising treatment modality for these patients40,41. 
A RCT conducted by Lee et al.42 evaluated the efficacy of a single injection of a 
1:3 mixture of genetically manipulated chondrocytes to express TGF-β1 and normal 
allogenic human chondrocytes against placebo in 54 patients with knee OA  concluding  
that in 24 weeks follow-up active treatment resulted in significantly pain and function 
improvement. Notwithstanding, an anaphylactic reaction to the preservation medium was 
reported in one patient. 
Two RCT evaluating the efficacy of intraarticular injections of polynucleotides 
compared to HA injections in a total of 135 randomized patients with knee OA showed 
similar results of both treatments in pain reduction43,44. 
A single RCT evaluated the effect of intra-articular injections of a mixture of 
sodium bicarbonate with a single or double dose of calcium gluconate concluding that 
this treatment is effective in reducing symptoms associated with OA. A higher dose of 
calcium gluconate is associated with further joint-space narrowing prevention. The 
positive effect of bicarbonate is attributed to its alkalinity whereas calcium gluconate 
avoid hyperosmotic conditions in extracellular matrix by allowing the linkage between 
chondrocytes and bone proteins45. Another RCT attempted 4 weekly intra-articular 
injection of a bisphosphonate (clodronate) resulting in a small and transient benefit over 
a 12 weeks follow-up compared to placebo46. A recent prospective study found etanercept 
(Tumor necrosis factor-alpha inhibitor) injections being more effective in pain 

























Intra-articular HA injections in knee osteoarthritis treatment are still a 
controversial issue due to the contradictory results obtained from different clinical trials. 
Of note, two RCT that showed no difference between HA injections and placebo used a 
hyaluronic acid formulation with a low molecular mass (sodium hyaluronate, Hyalgan® 
500 to 730 kDa)11 and medium molecular mass (2200 kDa)10, respectively. Another RCT 
that reported no difference between HA injections, saline distension and placebo used a 
HA formulation with a low molecular mass (Hyalgan®)21. On the other hand, all studies 
that used hyaluronic acid formulation with a high molecular mass (mean 6000 kDa) found 
positive effects in knee OA5,6,8,18-20. Therefore, molecular weight could represent a major 
issue in viscossuplementation. Previous studies had already suggested superiority of high 
molecular mass formulation of HA48 and this could explain the incongruent results from 
several systematic reviews and meta-analysis that do not differentiate HA formulations. 
An effusion at baseline do not affect HA effects if we aspire it previously5,8,17. 
CS injections remains among the literature reviewed an efficacious option to 
improve joint pain and function in a short-period and fast-acting basis, so far22,24,25. Some 
studies reinforce this short-acting improvement with no efficacy of CS injections against 
placebo over 12 weeks follow-up, though49. There is not consensus regarding which CS 
use, doses and frequency of injection, being still a individually tailor selection50. 
PRP is an autologous blood product with a high content of growth factors stored 
in alpha-granules of platelets and a low content of white blood cells (WBC), which is 
raising interest among physicians36. There are different PRP formulations with variable 
concentrations of growth factors and WBC33. This variability could affect the studies 
outcomes since a high content of WBC, which release proinflamatory cytokines, are 
associated with increased pain and swelling51,52. Our review were consistent with a 
positive effect of PRP injections in pain reduction and function improvement in knee OA. 
The RCTs reviewed all compared PRP with HA injections 27-30. Filardo et al.27 concluded 
PRP and HA injections being equal efficacious in knee OA, interestingly, the other three 
RCT that had positive results for PRP injections compared to HA injections used PRP 
formulations (Platelets rich in growth factor28,29 and autologous conditioned plasma30 ) 
with a higher content of growth factors and a lower content of WBC. These results put in 
perspective the importance of PRP formulations and cell/cytokines concentration in the 
final outcome. More studies are needed in this field to better understand which PRP 
formulation is the most effective. 
MSCs therapy is a promising treatment in knee OA since those are multipotent 
cells with capacity to differentiate in different cellular lines of mesodermal origin 
including cartilage, ligaments and tendon38. MSC could be autologous: bone marrow 
derived or adipose tissue derived with inconvenient related to the invasive bone marrow 
aspirations and adipose tissue extraction and also, MSC isolation and cell culture not 
suitable for an outpatient setting. In alternative other authors instead of isolating MSC, 
use bone marrow concentrates containing a fraction of MSC and other bone marrow cells 
(including hematopoietic stem cells, monocyte precursor cells, macrophages, T cells, B 
cells and others) with comparable results without MSC being isolated, suggesting that 
other bone marrow cells could affect tissue healing38.  Adipose-derived MSC are a 
promising alternative of autologous MSC therapies but further RCT studies are needed to 
access efficacy41. Allogeneic MSC are a cheaper and more convenient way for MSC 
intraarticular therapies. Despite the possibility of host immune rejection, MSC are 
immune evasive and inhibit immune responses. A RCT with 15 patients receiving 
allogenic MSC reported no safety concerns39. In spite of the potential of allogeneic MSC, 
larger RCT are needed to evaluate safety profile.  
Genetically manipulated chondrocytes expressing TGF-β are a recent treatment 
modality for knee OA. TGF-β is thought to have regenerative, anti-inflammatory and 
immunosuppressive properties, stimulating proteoglycan synthesis and growth of 
articular chondrocytes. This cell-mediated gene therapy consist of a mixture of transduced 
allogenic chondrocytes overexpressing TGF- β and normal allogenic chondrocytes. Non-
transduced chondrocytes are included to fill cartilage defects and act as an additional 
target for TGF-β signalling53. This therapy had promising results in a RCT and a phase 
two study, being sufficient for further clinical testing42,53.  
Intraarticular polynucleotides act as a 3D gel with a high content of water with 
mechanical effects in joint lubrication and moisturizing. In addition, polynucleotides 
provide synovial fluid with nucleotides, nucleosides, purine and pyrimidine that can 
therefore support the physiological repair processes of cartilage. Two RCT showed 
similar results of intraarticular polynucleotides compared to HA injections, being an 
alternative for this last treatment 43,44.  
Intra-articular etanercept had promising results in knee OA pain management, 
suggesting TNF-α is one factor that induces OA pain. However, one single trial was found 
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